Physician profile
Rudolph C Glattes
NPI 1346359460
$443,521.54
in general payments reported to CMS, 2019-2025
21 companies · $49K in 2025
The $49K reported for 2025 was more than what 95% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75K · 2020: $71K · 2021: $74K · 2022: $111K · 2023: $34K · 2024: $30K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $107K · Travel and Lodging: $2,451 · Food and Beverage: $2,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $107,293.77 |
| Travel and Lodging | $2,451.43 |
| Food and Beverage | $2,376.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seaspine Orthopedics Corporation | $328,196.87 | 2019-2022 | |
| Orthofix Medical, INC. | $107,709.10 | 2020-2025 | Malibu, Physio-Stim, Meridian |
| Arthrex, INC. | $2,180.34 | 2025 | |
| Medtronic USA, INC. | $1,826.23 | 2019-2020 | |
| Medtronic, INC. | $1,031.87 | 2021-2024 | Medtronic Reusable Instruments, Unid_pass, Anteralign Spinal System With Titan Nanolock Surface Technology |
| Music City Medical Technologies, LLC | $1,011.52 | 2024-2025 | |
| Intrinsic Therapeutics | $368.06 | 2025 | Barricaid Acd (Annular Closure Device) |
| Abyrx, INC | $275.75 | 2019 | |
| Baxter Healthcare | $220.26 | 2019 | |
| Alphatec Spine, INC | $185.91 | 2023 | Invictus Open |
| Cerapedics INC. | $147.38 | 2020 | |
| Abbvie INC. | $59.42 | 2024 | |
| Bioventus LLC | $53.51 | 2023 | Nexus, Bonescalpel |
| Horizon Therapeutics Plc | $51.07 | 2019-2020 | |
| Boston Scientific Corporation | $45.73 | 2023 | Wavewriter Alpha Prime 16 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $31.24 | 2025 | Pico |
| Vertex Pharmaceuticals Incorporated | $31.12 | 2025 | |
| Vericel Corporation | $28.59 | 2024 | Maci |
| Relievant Medsystems, INC. | $26.72 | 2021 | |
| Innovation Technologies INC | $21.83 | 2025 | Irrisept |
| Theragen, INC. | $19.02 | 2024 | Actastim-S |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rudolph Glattes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.